The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Once-weekly (70 mg/m2) versus twice-weekly (56 mg/m2) dosing of carfilzomib (CFZ) for patients (pts) with relapsed and/or refractory multiple myeloma (RRMM).
 
Philippe Moreau
Honoraria - Amgen; Celgene; Janssen-Cilag; Novartis; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen; Novartis; Takeda
 
A. Keith Stewart
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Roche
 
Meletios A. Dimopoulos
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen-Cilag; Takeda
 
David Samuel DiCapua Siegel
Stock and Other Ownership Interests - Celularity
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Karyopharm Therapeutics; Merck; Takeda
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Takeda
Research Funding - Celgene (Inst)
 
Thierry Facon
Consulting or Advisory Role - Amgen; Celgene; Janssen; Karyopharm Therapeutics; Oncopeptides; Sanofi; Takeda
Speakers' Bureau - celgene; Janssen; Takeda
 
James R. Berenson
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen
 
Noopur S. Raje
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen Oncology; Merck; Novartis; Takeda
Research Funding - AstraZeneca (Inst)
 
Jesus G. Berdeja
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); Celgene (Inst); crispr therapeutics (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); SERVIER (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); Bluebird Bio (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech/Roche (Inst); Glenmark (Inst); Janssen (Inst); Novartis (Inst); poseida therapeutics (Inst); Sanofi (Inst); Takeda (Inst); Teva (Inst)
 
Robert Z. Orlowski
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Janssen; Kite, a Gilead company; Sanofi; Takeda
Research Funding - Amgen; BioTheryX; Spectrum Pharmaceuticals
 
Hui Yang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Haijun Ma
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Zandra Karina Klippel
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Anita Zahlten-Kumeli
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Khalid Mezzi
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Karim Iskander
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Maria-Victoria Mateos
Honoraria - Amgen; Celgene; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Celgene; Janssen-Cilag; Takeda